Skip to main content

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Publication ,  Journal Article
Joshi, M-BM; Shirota, Y; Danenberg, KD; Conlon, DH; Salonga, DS; Herndon, JE; Danenberg, PV; Harpole, DH
Published in: Clin Cancer Res
March 15, 2005

PURPOSE: To assess the relationship between molecular markers associated with chemotherapy resistance and survival in esophageal cancer patients treated with trimodality therapy. EXPERIMENTAL DESIGN: The original pretreatment formalin-fixed, paraffin-embedded endoscopic esophageal tumor biopsy material was obtained from 99 patients treated with concurrent cisplatin plus 5-fluorouracil plus 45 Gy radiation followed by resection at Duke University Medical Center (Durham, NC) from 1986 to 1997. cDNA was derived from the biopsy and analyzed to determine mRNA expression relative to an internal reference gene (beta-actin) using fluorescence-based, real-time reverse transcription-PCR. Possible markers of platinum chemotherapy association [glutathione S-transferase pi (GSTP1) and excision cross-complementing gene 1 (ERCC1)] and 5-fluorouracil association [thymidylate synthase 1 (TS1)] were measured. RESULTS: Cox proportional hazards model revealed a significant inverse, linear effect for TS1 with respect to survival (P = 0.007). An inverse relationship between TS1 expression and treatment response was also detected (P < or = 0.001). Univariate analysis identified an association with decreased survival for GSTP1 > or = 3.0 (P = 0.05). In multivariate analyses, TS1 >6.0, ERCC1 >3, and GSTP1 >3 were statistically significant predictors of decreased survival (P = 0.007). Additionally, the presence of ERCC1 >3.0 or TS1 >6.0 was associated with an approximately 2-fold increase in the risk of cancer recurrence (P = 0.086 and 0.003, respectively). CONCLUSION: The measurement of relative gene expression of molecular markers associated with chemoresistance in endoscopic esophageal tumor biopsies may be a useful tool in assessing outcome in patients with trimodality-treated esophageal cancer. These data should be validated further in larger prospective studies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

March 15, 2005

Volume

11

Issue

6

Start / End Page

2215 / 2221

Location

United States

Related Subject Headings

  • Thymidylate Synthase
  • Survival Rate
  • Risk Factors
  • RNA, Messenger
  • Prognosis
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Isoenzymes
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Joshi, M.-B., Shirota, Y., Danenberg, K. D., Conlon, D. H., Salonga, D. S., Herndon, J. E., … Harpole, D. H. (2005). High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 11(6), 2215–2221. https://doi.org/10.1158/1078-0432.CCR-04-1387
Joshi, Mary-Beth Moore, Yoshinori Shirota, Kathleen D. Danenberg, Debbi H. Conlon, Dennis S. Salonga, James E. Herndon, Peter V. Danenberg, and David H. Harpole. “High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.Clin Cancer Res 11, no. 6 (March 15, 2005): 2215–21. https://doi.org/10.1158/1078-0432.CCR-04-1387.
Joshi M-BM, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005 Mar 15;11(6):2215–21.
Joshi, Mary-Beth Moore, et al. “High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.Clin Cancer Res, vol. 11, no. 6, Mar. 2005, pp. 2215–21. Pubmed, doi:10.1158/1078-0432.CCR-04-1387.
Joshi M-BM, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005 Mar 15;11(6):2215–2221.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

March 15, 2005

Volume

11

Issue

6

Start / End Page

2215 / 2221

Location

United States

Related Subject Headings

  • Thymidylate Synthase
  • Survival Rate
  • Risk Factors
  • RNA, Messenger
  • Prognosis
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Isoenzymes
  • Humans